13.3.2017
EN
Official Journal of the European Union
C 78/29
Judgment of the General Court of 26 January 2017 — Opko Ireland Global Holdings v EUIPO — Teva Pharmaceutical Industries (ALPHAREN)
(Case T-88/16) (1)
((EU trade mark - Opposition proceedings - Application for EU word mark ALPHAREN - Earlier national word marks ALPHA D3 - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EC) No 207/2009 - Consideration of new evidence by the Board of Appeal following a judgment annulling a decision - Article 76(2) of Regulation No 207/2009))
(2017/C 078/40)
Language of the case: English
Parties
Applicant: Opko Ireland Global Holdings Ltd (Dublin, Ireland) (represented by: S. Malynicz QC, A. Smith and D. Meale, Solicitors)
Defendant: European Union Intellectual Property Office (represented by: A. Folliard-Monguiral, acting as Agent)
Other party to the proceedings before the Board of Appeal of EUIPO: Teva Pharmaceutical Industries Ltd (Jerusalem, Israel)
Re:
Action brought against the decision of the Fifth Board of Appeal of EUIPO of 16 December 2015 (Case R 2387/2014-5), relating to opposition proceedings between Teva Pharmaceutical Industries and Opko Ireland Global Holdings.
Operative part of the judgment
The Court:
1.
Dismisses the action;
2.
Orders Opko Ireland Global Holdings Ltd to pay the costs.
(1) OJ C 136, 18.4.2016.